Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Keymed Biosciences's share price for the quarter that ended in Dec. 2025 was HK$53.1. Keymed Biosciences's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 294.6 Mil. Therefore, Keymed Biosciences's market cap for the quarter that ended in Dec. 2025 was HK$15,643.3 Mil.
Keymed Biosciences's quarterly market cap
increased
from Dec. 2024 (HK$8,571.2 Mil) to Jun. 2025 (HK$13,610.5 Mil) and
increased
from Jun. 2025 (HK$13,610.5 Mil) to Dec. 2025 (HK$15,643.3 Mil).
Keymed Biosciences's annual market cap
declined
from Dec. 2023 (HK$13,581.3 Mil) to Dec. 2024 (HK$8,571.2 Mil) but then
increased
from Dec. 2024 (HK$8,571.2 Mil) to Dec. 2025 (HK$15,643.3 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Keymed Biosciences's Enterprise Value for Today is HK$21,159.9 Mil.
Keymed Biosciences (HKSE:02162) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Keymed Biosciences Market Cap Related Terms
Keymed Biosciences Market Cap Historical Data
* Premium members only.
The historical data trend for Keymed Biosciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02162 vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, Keymed Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Keymed Biosciences Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Keymed Biosciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Keymed Biosciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Keymed Biosciences's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keymed Biosciences (HKSE:02162) has a Market Cap of HK$22,993.5 Mil as of Aug. 05, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Keymed Biosciences and its competitors. According to the industry distribution chart, Keymed Biosciences ranks #126 out of 1423 companies in the Biotechnology industry, placing it in the top 8.9%.
Is Keymed Biosciences' Market Cap too high?
Keymed Biosciences' current Market Cap is HK$22,993.5 Mil. Based on the distribution chart, Keymed Biosciences ranks #126 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Keymed Biosciences has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Keymed Biosciences' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Keymed Biosciences ranks #126 out of 1423 companies for Market Cap. This places Keymed Biosciences in the top 9% of its industry — outperforming the majority of peers. The industry median Market Cap is 117.58. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.58, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Keymed Biosciences and its competitors. For the Biotechnology industry, the median Market Cap is 117.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Keymed Biosciences's current Market Cap is HK$22,993.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keymed Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Keymed Biosciences (HKSE:02162) is currently considered Possible Value Trap. The stock's GF Value™ is HK$173.29, compared to a current price of HK$78.05 — trading 55% below its estimated fair value. The current Market Cap is HK$22,993.5 Mil. Keymed Biosciences' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Keymed Biosciences (HKSE:02162), the current Market Cap is HK$22,993.5 Mil as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Keymed Biosciences (HKSE:02162) Overvalued in 2026?
Based on GuruFocus' analysis, Keymed Biosciences stock appears to be undervalued.
The current stock price of HK$78.05 is trading 55% below its estimated GF Value™ of HK$173.29.
GuruFocus considers Keymed Biosciences to be Possible Value Trap.
Key valuation signals for HKSE:02162:
Market Cap: HK$22,993.5 Mil
GF Value™: HK$173.29 vs. price of HK$78.05 (55% below fair value)
No single metric tells the full story. See the HKSE:02162 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
46GF Score
Get the complete analysis for HKSE:02162
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02162 has been successfully added to your 
